FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998994416> ?p ?o ?g. }

• W1998994416 endingPage "882" @default.
• W1998994416 startingPage "877" @default.
• W1998994416 abstract "Purpose Hypofractionated radiotherapy has an intrinsically different normal tissue and tumor radiobiology. The results of a prospective trial of stereotactic body radiotherapy (SBRT) for prostate cancer with long-term patient-reported toxicity and tumor control rates are presented. Methods and Materials From 2003 through 2009, 67 patients with clinically localized low-risk prostate cancer were enrolled. Treatment consisted of 36.25 Gy in 5 fractions using SBRT with the CyberKnife as the delivery technology. No patient received hormone therapy. Patient self-reported bladder and rectal toxicities were graded on the Radiation Therapy Oncology Group scale (RTOG). Results Median follow-up was 2.7 years. There were no grade 4 toxicities. Radiation Therapy Oncology Group Grade 3, 2, and 1 bladder toxicities were seen in 3% (2 patients), 5% (3 patients), and 23% (13 patients) respectively. Dysuria exacerbated by urologic instrumentation accounted for both patients with Grade 3 toxicity. Urinary incontinence, complete obstruction, or persistent hematuria was not observed. Rectal Grade 3, 2, and 1 toxicities were seen in 0, 2% (1 patient), and 12.5% (7 patients), respectively. Persistent rectal bleeding was not observed. Low-grade toxicities were substantially less frequent with QOD vs. QD dose regimen (p = 0.001 for gastrointestinal and p = 0.007 for genitourinary). There were two prostate-specific antigen (PSA), biopsy-proven failures with negative metastatic workup. Median PSA at follow-up was 0.5 ± 0.72 ng/mL. The 4-year Kaplan-Meier PSA relapse-free survival was 94% (95% confidence interval, 85%–102%). Conclusion Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent. PSA relapse-free survival compares favorably with other definitive treatments. The current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer. Hypofractionated radiotherapy has an intrinsically different normal tissue and tumor radiobiology. The results of a prospective trial of stereotactic body radiotherapy (SBRT) for prostate cancer with long-term patient-reported toxicity and tumor control rates are presented. From 2003 through 2009, 67 patients with clinically localized low-risk prostate cancer were enrolled. Treatment consisted of 36.25 Gy in 5 fractions using SBRT with the CyberKnife as the delivery technology. No patient received hormone therapy. Patient self-reported bladder and rectal toxicities were graded on the Radiation Therapy Oncology Group scale (RTOG). Median follow-up was 2.7 years. There were no grade 4 toxicities. Radiation Therapy Oncology Group Grade 3, 2, and 1 bladder toxicities were seen in 3% (2 patients), 5% (3 patients), and 23% (13 patients) respectively. Dysuria exacerbated by urologic instrumentation accounted for both patients with Grade 3 toxicity. Urinary incontinence, complete obstruction, or persistent hematuria was not observed. Rectal Grade 3, 2, and 1 toxicities were seen in 0, 2% (1 patient), and 12.5% (7 patients), respectively. Persistent rectal bleeding was not observed. Low-grade toxicities were substantially less frequent with QOD vs. QD dose regimen (p = 0.001 for gastrointestinal and p = 0.007 for genitourinary). There were two prostate-specific antigen (PSA), biopsy-proven failures with negative metastatic workup. Median PSA at follow-up was 0.5 ± 0.72 ng/mL. The 4-year Kaplan-Meier PSA relapse-free survival was 94% (95% confidence interval, 85%–102%). Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent. PSA relapse-free survival compares favorably with other definitive treatments. The current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer." @default.
• W1998994416 created "2016-06-24" @default.
• W1998994416 creator A5001887362 @default.
• W1998994416 creator A5022762690 @default.
• W1998994416 creator A5023026845 @default.
• W1998994416 creator A5075025160 @default.
• W1998994416 date "2012-02-01" @default.
• W1998994416 modified "2023-10-04" @default.
• W1998994416 title "Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer" @default.
• W1998994416 cites W1697031358 @default.
• W1998994416 cites W1989895459 @default.
• W1998994416 cites W1996210252 @default.
• W1998994416 cites W2002612178 @default.
• W1998994416 cites W2018393095 @default.
• W1998994416 cites W2020242089 @default.
• W1998994416 cites W2025691442 @default.
• W1998994416 cites W2027570282 @default.
• W1998994416 cites W2034771449 @default.
• W1998994416 cites W2039139527 @default.
• W1998994416 cites W2045468595 @default.
• W1998994416 cites W2051154636 @default.
• W1998994416 cites W2054899405 @default.
• W1998994416 cites W2083445933 @default.
• W1998994416 cites W2096568394 @default.
• W1998994416 cites W2097532477 @default.
• W1998994416 cites W2098733695 @default.
• W1998994416 cites W2104874527 @default.
• W1998994416 cites W2115675646 @default.
• W1998994416 cites W2130574795 @default.
• W1998994416 cites W2152182740 @default.
• W1998994416 cites W2159598747 @default.
• W1998994416 cites W2160406420 @default.
• W1998994416 doi "https://doi.org/10.1016/j.ijrobp.2010.11.054" @default.
• W1998994416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21300474" @default.
• W1998994416 hasPublicationYear "2012" @default.
• W1998994416 type Work @default.
• W1998994416 sameAs 1998994416 @default.
• W1998994416 citedByCount "335" @default.
• W1998994416 countsByYear W19989944162012 @default.
• W1998994416 countsByYear W19989944162013 @default.
• W1998994416 countsByYear W19989944162014 @default.
• W1998994416 countsByYear W19989944162015 @default.
• W1998994416 countsByYear W19989944162016 @default.
• W1998994416 countsByYear W19989944162017 @default.
• W1998994416 countsByYear W19989944162018 @default.
• W1998994416 countsByYear W19989944162019 @default.
• W1998994416 countsByYear W19989944162020 @default.
• W1998994416 countsByYear W19989944162021 @default.
• W1998994416 countsByYear W19989944162022 @default.
• W1998994416 countsByYear W19989944162023 @default.
• W1998994416 crossrefType "journal-article" @default.
• W1998994416 hasAuthorship W1998994416A5001887362 @default.
• W1998994416 hasAuthorship W1998994416A5022762690 @default.
• W1998994416 hasAuthorship W1998994416A5023026845 @default.
• W1998994416 hasAuthorship W1998994416A5075025160 @default.
• W1998994416 hasConcept C121608353 @default.
• W1998994416 hasConcept C126322002 @default.
• W1998994416 hasConcept C126894567 @default.
• W1998994416 hasConcept C133507102 @default.
• W1998994416 hasConcept C141071460 @default.
• W1998994416 hasConcept C143998085 @default.
• W1998994416 hasConcept C188816634 @default.
• W1998994416 hasConcept C2776235491 @default.
• W1998994416 hasConcept C2776651944 @default.
• W1998994416 hasConcept C2776845205 @default.
• W1998994416 hasConcept C2780101318 @default.
• W1998994416 hasConcept C2780192828 @default.
• W1998994416 hasConcept C2780387249 @default.
• W1998994416 hasConcept C2781413609 @default.
• W1998994416 hasConcept C509974204 @default.
• W1998994416 hasConcept C71924100 @default.
• W1998994416 hasConcept C77411442 @default.
• W1998994416 hasConceptScore W1998994416C121608353 @default.
• W1998994416 hasConceptScore W1998994416C126322002 @default.
• W1998994416 hasConceptScore W1998994416C126894567 @default.
• W1998994416 hasConceptScore W1998994416C133507102 @default.
• W1998994416 hasConceptScore W1998994416C141071460 @default.
• W1998994416 hasConceptScore W1998994416C143998085 @default.
• W1998994416 hasConceptScore W1998994416C188816634 @default.
• W1998994416 hasConceptScore W1998994416C2776235491 @default.
• W1998994416 hasConceptScore W1998994416C2776651944 @default.
• W1998994416 hasConceptScore W1998994416C2776845205 @default.
• W1998994416 hasConceptScore W1998994416C2780101318 @default.
• W1998994416 hasConceptScore W1998994416C2780192828 @default.
• W1998994416 hasConceptScore W1998994416C2780387249 @default.
• W1998994416 hasConceptScore W1998994416C2781413609 @default.
• W1998994416 hasConceptScore W1998994416C509974204 @default.
• W1998994416 hasConceptScore W1998994416C71924100 @default.
• W1998994416 hasConceptScore W1998994416C77411442 @default.
• W1998994416 hasIssue "2" @default.
• W1998994416 hasLocation W19989944161 @default.
• W1998994416 hasLocation W19989944162 @default.
• W1998994416 hasOpenAccess W1998994416 @default.
• W1998994416 hasPrimaryLocation W19989944161 @default.
• W1998994416 hasRelatedWork W1584199614 @default.
• W1998994416 hasRelatedWork W1980188241 @default.
• W1998994416 hasRelatedWork W1992657261 @default.
• W1998994416 hasRelatedWork W1994448744 @default.

• next